Alvotech is trading at ISK 490.00 (+4.03%) ahead of its August 19 H1 2026 results and August 20 webcast.
- The update highlighted FDA resubmissions for AVT05, AVT06, and partner-led AVT03, with Q4 2026 decision targets.
- FDA accepted AVT16 and classified the Reykjavik inspection VAI.
- H1 revenue fell 30.8% year over year, making the move likely anticipation of pipeline and financing progress.